Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2017 Apr 4

PMID 28367455

Citations 20

Authors

Yuchen Xia

Xiaoming Cheng

Christoph K Blossey

Karin Wisskirchen

Knud Esser

Ulrike Protzer

Affiliations

Soon will be listed here.

Abstract

Interferon- (IFN-) has been used for more than 20 years as the first-line therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, because it has a number of antiviral effects. In this study, we describe a novel mode of its antiviral action. We demonstrate that the supernatant from IFN--treated cultured cells restricted HBV and HCV infection by inhibiting viral entry into hepatoma cells. The factors contained in the supernatant competed with the virus for binding to heparan glycosaminoglycans-the nonspecific attachment step shared by HBV and HCV. Secreted factors of high molecular mass that bind to heparin columns elicited the antiviral effect. In conclusion, IFN- is able to induce soluble factors that can bind to heparan glycosaminoglycans thus leading to the inhibition of viral binding.

Citing Articles

SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription.

Li A, Zhao K, Duan Y, Zhang B, Zheng Y, Zhu C J Virol. 2024; 98(11):e0104224.

PMID: 39373477 PMC: 11575256. DOI: 10.1128/jvi.01042-24.

Hepatitis B virus RNAs co-opt ELAVL1 for stabilization and CRM1-dependent nuclear export.

Zheng Y, Wang M, Yin J, Duan Y, Wu C, Xu Z PLoS Pathog. 2024; 20(2):e1011999.

PMID: 38306394 PMC: 10866535. DOI: 10.1371/journal.ppat.1011999.

IL2-inducible T-cell Kinase is Required for HBV-induced Type T Interferon Expression and Antiviral Response.

Lin M, Guo R, Zeng D, Liu J, Zheng M, Su Z J Clin Transl Hepatol. 2023; 11(4):918-924.

PMID: 37408826 PMC: 10318274. DOI: 10.14218/JCTH.2022.00299.

Hepatitis B virus hijacks TSG101 to facilitate egress via multiple vesicle bodies.

Zheng Y, Wang M, Li S, Bu Y, Xu Z, Zhu G PLoS Pathog. 2023; 19(5):e1011382.

PMID: 37224147 PMC: 10208485. DOI: 10.1371/journal.ppat.1011382.

Antibiotic-induced gut bacteria depletion has no effect on HBV replication in HBV immune tolerance mouse model.

Bu Y, Zhao K, Xu Z, Zheng Y, Hua R, Wu C Virol Sin. 2023; 38(3):335-343.

PMID: 37141990 PMC: 10311260. DOI: 10.1016/j.virs.2023.04.010.

References

Li W, Urban S . Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol. 2016; 64(1 Suppl):S32-S40. PMC: 7114860. DOI: 10.1016/j.jhep.2016.02.011. View

Xia Y, Protzer U . Control of Hepatitis B Virus by Cytokines. Viruses. 2017; 9(1). PMC: 5294987. DOI: 10.3390/v9010018. View

Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M . Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011; 55(5):996-1003. DOI: 10.1016/j.jhep.2011.02.015. View

Marsh M, Helenius A . Virus entry: open sesame. Cell. 2006; 124(4):729-40. PMC: 7112260. DOI: 10.1016/j.cell.2006.02.007. View

Schulze A, Gripon P, Urban S . Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007; 46(6):1759-68. DOI: 10.1002/hep.21896. View

Der S, Zhou A, Williams B, Silverman R . Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998; 95(26):15623-8. PMC: 28094. DOI: 10.1073/pnas.95.26.15623. View

Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C . Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013; 9(9):e1003613. PMC: 3771898. DOI: 10.1371/journal.ppat.1003613. View

Xia Y, Lucifora J, Reisinger F, Heikenwalder M, Protzer U . Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA". Science. 2014; 344(6189):1237. DOI: 10.1126/science.1254083. View

Barth H, Schafer C, Adah M, Zhang F, Linhardt R, Toyoda H . Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem. 2003; 278(42):41003-12. DOI: 10.1074/jbc.M302267200. View

10.

Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E . Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A. 2006; 103(19):7408-13. PMC: 1455439. DOI: 10.1073/pnas.0504877103. View

11.

Platanias L . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5(5):375-86. DOI: 10.1038/nri1604. View

12.

Isaacs A, Lindenmann J . Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957; 147(927):258-67. DOI: 10.1098/rspb.1957.0048. View

13.

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M . Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016; 65(3):490-8. DOI: 10.1016/j.jhep.2016.04.016. View

14.

Uprichard S, Wieland S, Althage A, Chisari F . Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A. 2003; 100(3):1310-5. PMC: 298769. DOI: 10.1073/pnas.252773599. View

15.

Wieland S, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari F . Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A. 2005; 102(28):9913-7. PMC: 1175012. DOI: 10.1073/pnas.0504273102. View

16.

Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L . Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol. 2007; 82(4):1665-78. PMC: 2258705. DOI: 10.1128/JVI.02113-07. View

17.

Wilkins C, Woodward J, Lau D, Barnes A, Joyce M, McFarlane N . IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2012; 57(2):461-9. PMC: 3566288. DOI: 10.1002/hep.26066. View

18.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X . Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176):1221-8. PMC: 6309542. DOI: 10.1126/science.1243462. View

19.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

20.

Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R . Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog. 2013; 9(7):e1003494. PMC: 3708887. DOI: 10.1371/journal.ppat.1003494. View